Silence Therapeutics (NASDAQ:SLN) Earns “Buy” Rating from HC Wainwright

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $75.00 price objective on the stock.

A number of other analysts have also recently commented on SLN. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research report on Tuesday. BMO Capital Markets reduced their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. Morgan Stanley reduced their price objective on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Silence Therapeutics has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Price Performance

SLN stock opened at $4.74 on Friday. The stock has a market capitalization of $141.87 million, a P/E ratio of -3.02 and a beta of 1.08. The business has a fifty day moving average price of $5.44 and a 200-day moving average price of $11.48. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC lifted its position in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares in the last quarter. Barclays PLC boosted its position in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after buying an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Silence Therapeutics in the 4th quarter valued at about $69,000. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after purchasing an additional 6,098 shares in the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.